Parecoxib and Imrecoxib Sequential Therapy: A Breakthrough in Managing Severe Acute Pancreatitis
Highlight
– Sequential administration of parecoxib followed by imrecoxib significantly reduced the occurrence of severe acute pancreatitis (SAP) by 20.7% compared to placebo.
– The duration of persistent organ failure (OF) was shortened by two days in patients treated with COX-2 inhibitors.
– Local complications and systemic inflammatory mediators were notably less frequent and reduced, respectively, after COX-2-Is treatment.
– The 30-day mortality rate dropped from 8.6% in the placebo group to 3.4% with sequential COX-2 inhibitor therapy, with a similar adverse event profile between treatment groups.
Study Background and Disease Burden
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.